Infinium Pharmachem Limited

NSE: INFINIUM
Infinium Pharmachem Limited - pharma in Sojitra, Gujarat, India. FY 2026 financials & compliance.
CIN L24231GJ2003PLC043218 Incorporated 21 November 2003 ROC Ahmedabad HQ Sojitra, Gujarat, India
Active Listed - NSE: INFINIUM Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹438 Cr
INFINIUM-ST · NSE
Share Price
₹272.95
-2.86% today
Revenue
₹190 Cr
FY 2025-26 · +21.8% YoY
EBITDA
₹21.56 Cr
Margin 11.4%
Net Profit
₹12.15 Cr
FY 2025-26 · +20.8% YoY
P/E (TTM)
35.3x
P/B 3.5x
Authorised capital
₹25 Cr
Registered with MCA
Paid-up capital
₹15.58 Cr
Issued & subscribed

About Infinium Pharmachem Limited

Data last updated:

Infinium Pharmachem Limited is a public limited company based in Sojitra, Gujarat, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 21 November 2003 and has been in existence for over 23 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ2003PLC043218. Its GSTIN is 24AABCI1843B1Z8 (Gujarat). It is a listed company as per MCA records. Its shares are listed on NSE: INFINIUM.

The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹15.58 Cr. It is led by directors including Sanjaykumar Viththalbhai Patel (Managing Director) and Pravin Bhadabhai Madhani.

Its last annual general meeting (AGM) was held on 17 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 38 G I D C Sojitra Taluka: Sojitra Dist: Anand, Gujarat, India – 387240.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹189.63 Cr, a growth of 21.8% compared to the previous year. For the same year it recorded a net profit of ₹12.15 Cr (net margin 6.4%) and EBITDA of ₹21.56 Cr (EBITDA margin 11.4%). The net worth stands at ₹121.04 Cr (up 10.6% YoY). Total assets are valued at ₹161.48 Cr (down 8.6% YoY).

The company has about 93 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Infinium Pharmachem. As per MCA filings, the company has open charges of ₹92.6 Cr and satisfied charges of ₹65.68 Cr on record. The company has 1 deal on record (1 ipo); the latest was in April 2023. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Syntho Chirals Private Limited with revenue of ₹162.38 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 8 overdue payments to 6 micro and small suppliers.

Infinium Pharmachem Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-03-0002712). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website infiniumpharmachem.com.

Company details

CIN L24231GJ2003PLC043218
Registration Number 043218
Incorporation Date 21 November 2003
ROC Ahmedabad
Listing Status Listed (NSE: INFINIUM)
Company Status Active
Date of Last AGM 17 September 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-03-0002712

CIN history

Infinium Pharmachem has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231GJ2003PLC043218, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231GJ2003PLC043218Current
U24231GJ2003PTC043218Previous
U24231GJ2003PLC043218Previous
Key People
Sanjaykumar Viththalbhai Patel Managing Director Pravin Bhadabhai Madhani Director Mitesh Lavjibhai Chikhaliya Director

Recognitions & Rankings of Infinium Pharmachem

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-GJ-03-0002712

Contact details

Infinium Pharmachem Limited's registered office is in Sojitra, Gujarat. Its website is infiniumpharmachem.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    infiniumpharmachem.com
  • Social Media
  • Registered Address
    38 G I D C Sojitra Taluka: Sojitra Dist: Anand, Gujarat, India – 387240
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Infinium Pharmachem Limited, buy the company report.

Comprehensive company report
Infinium Pharmachem Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Infinium Pharmachem operates one associated brand: Infinium Pharmachem. Each brand links to its own profile.

BrandDescriptionWebsite
Infinium Pharmachem
Iodine derivatives are developed, manufactured, and exported for pharmaceutical industries.infiniumpharmachem.com

Business activity

The main business activity of Infinium Pharmachem is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Infinium Pharmachem Limited, buy the company report.

Financials of Infinium Pharmachem Limited

FY 2025-26 filings available

Infinium Pharmachem Limited reported revenue of ₹189.63 Cr (up 21.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹190 Cr
+21.8% YoY
EBITDA
₹21.56 Cr
+30.7% YoY
Profit After Tax
₹12.15 Cr
+20.8% YoY
Net Worth
₹121 Cr
+10.6% YoY
Total Assets
₹161 Cr
-8.6% YoY
Total Debt
₹22.86 Cr
-55.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19015613611499.1270.5338.84
Revenue growth+21.8%+14.8%+18.8%+15.2%+40.5%+81.6%-
EBITDA21.5616.4918.5416.0510.034.962.48
EBITDA margin+11.4%+10.6%+13.7%+14.1%+10.1%+7.0%+6.4%
Profit before tax17.8411.5915.2212.968.633.771.23
Net profit12.1510.0611.329.496.102.720.93
Net profit margin+6.4%+6.5%+8.4%+8.3%+6.2%+3.9%+2.4%
EPS (₹)7.805.238.1218.6760.0726.809.19
Balance sheet
Total assets16117771.4853.0236.4417.7313.20
Net worth12110958.7822.5613.117.034.25
Total debt22.8651.8511.2429.2422.5210.518.86
Cash & bank29.7834.8411.915.985.451.990.86
Net working capital96.5411851.0233.7221.139.028.93
Cash flow
Cash from operations33.73(29.14)(13.04)8.5911.807.293.03
Cash from investing(7.24)(27.22)(3.79)(4.96)(6.63)(5.00)(1.05)
Cash from financing(31.56)79.2922.77(3.10)(1.70)(1.16)(1.24)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue15613712210174.0454.5636.04
Revenue growth+14.3%+11.9%+20.8%+36.8%+35.7%+51.4%-
EBITDA16.9715.1817.4215.218.714.922.64
EBITDA margin+10.9%+11.1%+14.2%+15.0%+11.8%+9.0%+7.3%
Profit before tax13.5211.6114.8612.267.403.771.40
Net profit10.038.4811.109.145.502.731.03
Net profit margin+6.4%+6.2%+9.1%+9.0%+7.4%+5.0%+2.9%
EPS (₹)6.435.437.9718.0054.1326.7510.01
Balance sheet
Total assets-15165.6947.7935.0717.5613.18
Net worth-10657.7621.7012.557.054.32
Total debt-45.357.9426.1022.5210.518.86
Cash & bank-33.298.183.321.541.240.14
Net working capital-11348.2431.3819.949.078.66
Cash flow
Cash from operations-(25.95)(15.03)7.359.146.822.32
Cash from investing-(23.15)(3.29)(2.58)(7.17)(4.59)(1.08)
Cash from financing-74.2123.19(3.00)(1.66)(1.12)(1.23)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19015613611499.1270.5338.84
Revenue growth+21.8%+14.8%+18.8%+15.2%+40.5%+81.6%-
Other income2.142.121.541.350.930.620.57
Total expenses16813911798.1789.0965.5736.36
Employee cost0.007.435.915.373.542.752.09
EBITDA21.5616.4918.5416.0510.034.962.48
EBITDA margin+11.4%+10.6%+13.7%+14.1%+10.1%+7.0%+6.4%
Depreciation3.063.292.671.340.630.650.58
Interest2.803.732.193.101.701.161.24
Profit before tax17.8411.5915.2212.968.633.771.23
Tax3.643.733.703.141.951.040.37
Net profit12.1510.0611.329.496.102.720.93
Net profit margin+6.4%+6.5%+8.4%+8.3%+6.2%+3.9%+2.4%
EPS (₹)7.805.238.1218.6760.0726.809.19
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.5815.5813.925.081.021.021.02
Reserves & surplus10593.8844.8617.4812.096.013.23
Shareholders' funds (net worth)12110958.7822.5613.117.034.25
Minority interest17.4115.331.451.220.820.190.09
Secured loans10.8135.7010.6825.3819.286.604.26
Unsecured loans12.0516.150.563.863.243.914.60
Total debt22.8651.8511.2429.2422.5210.518.86
Total liabilities16117771.4853.0236.4417.7313.20
Assets
Gross block37.8235.4427.2524.198.248.136.93
Net block23.4724.1619.6418.814.204.724.16
Capital work in progress8.160.850.020.008.483.860.00
Investments29.0229.020.000.000.000.000.00
Inventories39.0544.2524.6919.7216.369.386.90
Sundry debtors31.4633.7520.4515.4315.3911.497.93
Cash & bank balances29.7834.8411.915.985.451.990.86
Loans & advances9.7127.077.9510.186.482.612.48
Total current assets11014065.0051.3143.6825.4718.17
Total current liabilities13.4621.7413.9817.5922.5516.459.24
Net working capital96.5411851.0233.7221.139.028.93
Total assets16117771.4853.0236.4417.7313.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash34.8411.915.985.451.990.860.12
Net cash from operating activities33.73(29.14)(13.04)8.5911.807.293.03
Net cash from investing activities(7.24)(27.22)(3.79)(4.96)(6.63)(5.00)(1.05)
Net cash from financing activities(31.56)79.2922.77(3.10)(1.70)(1.16)(1.24)
Net change in cash(5.06)22.935.930.533.461.130.74
Closing cash29.7834.8411.915.985.451.990.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+21.8%+14.8%+18.8%+15.2%+40.5%+81.6%-
EBITDA growth+30.8%-11.1%+15.5%+60.0%+102.2%+100.0%-
PBT growth+53.9%-23.9%+17.4%+50.2%+128.9%+206.5%+9997.0%
Net income growth+20.8%-11.1%+19.3%+55.6%+124.3%+192.5%-
Revenue CAGR (3Y)+18.4%+16.3%+24.4%+43.3%---
EBITDA CAGR (3Y)+10.3%+18.0%+55.2%+86.4%---
Profitability & leverage
Net income margin+7.5%+5.1%+8.5%+8.6%+6.7%+3.9%+2.2%
Return on capital employed-+15.6%+28.6%+36.7%+38.9%+32.2%+18.9%
Return on net worth-+11.6%+28.3%+55.1%+66.4%+48.4%+20.5%
Debt / equity-0.380.501.451.641.722.08
Long-term debt / equity-0.110.220.660.961.011.33
Interest cover15.1428.2613.8021.0718.0926.9165.26
Efficiency & per share
Fixed asset turnover-4.975.277.0412.119.375.60
Inventory turnover-4.526.116.337.708.665.63
Debtors turnover-5.757.567.417.387.264.90
EPS (₹)7.805.238.1218.6760.0726.809.19
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0070.2542.2444.39128.8869.0941.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue15613712210174.0454.5636.04
Revenue growth+14.3%+11.9%+20.8%+36.8%+35.7%+51.4%-
Other income1.412.131.631.340.930.620.57
Total expenses13912210586.1065.3349.6433.40
Employee cost0.005.034.563.673.162.211.85
EBITDA16.9715.1817.4215.218.714.922.64
EBITDA margin+10.9%+11.1%+14.2%+15.0%+11.8%+9.0%+7.3%
Depreciation2.572.982.411.290.580.650.58
Interest2.292.721.783.001.661.121.23
Profit before tax13.5211.6114.8612.267.403.771.40
Tax3.493.133.763.121.901.040.37
Net profit10.038.4811.109.145.502.731.03
Net profit margin+6.4%+6.2%+9.1%+9.0%+7.4%+5.0%+2.9%
EPS (₹)6.435.437.9718.0054.1326.7510.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-15.5813.925.081.021.021.02
Reserves & surplus-90.1343.8416.6211.536.033.30
Shareholders' funds (net worth)-10657.7621.7012.557.054.32
Secured loans-32.897.9422.7519.286.604.26
Unsecured loans-12.460.003.353.243.914.60
Total debt-45.357.9426.1022.5210.518.86
Total liabilities-15165.6947.7935.0717.5613.18
Assets
Gross block-27.6824.1020.857.737.666.93
Net block-17.0616.4715.583.744.254.16
Capital work in progress-0.850.020.008.483.860.00
Investments-15.660.340.340.260.260.26
Inventories-35.1822.4817.9114.238.676.73
Sundry debtors-34.4123.8115.1612.9510.437.41
Cash & bank balances-33.298.183.321.541.240.14
Loans & advances-25.415.767.615.211.981.78
Total current assets-12860.2344.0033.9322.3216.06
Total current liabilities-15.0611.9912.6213.9913.257.40
Net working capital-11348.2431.3819.949.078.66
Total assets-15165.6947.7935.0717.5613.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-8.183.321.541.240.140.12
Net cash from operating activities-(25.95)(15.03)7.359.146.822.32
Net cash from investing activities-(23.15)(3.29)(2.58)(7.17)(4.59)(1.08)
Net cash from financing activities-74.2123.19(3.00)(1.66)(1.12)(1.23)
Net change in cash-25.114.861.770.311.100.02
Closing cash-33.298.183.321.541.240.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.3%+11.9%+20.8%+36.8%+35.7%+51.4%-
EBITDA growth+11.8%-12.9%+14.5%+74.6%+77.0%+86.4%-
PBT growth+16.5%-21.9%+21.2%+65.7%+96.3%+169.3%+9997.0%
Net income growth+18.3%-23.6%+21.4%+66.2%+101.5%+165.1%-
Revenue CAGR (3Y)+15.6%+22.7%+30.9%+41.1%---
EBITDA CAGR (3Y)+3.7%+20.3%+52.4%+79.3%---
Profitability & leverage
Net income margin+6.4%+6.2%+9.1%+9.0%+7.4%+5.0%+2.9%
Return on capital employed-+13.2%+29.3%+36.9%+34.4%+31.8%+19.9%
Return on net worth-+10.4%+27.9%+53.4%+56.1%+47.9%+23.6%
Debt / equity-0.330.431.421.691.702.05
Long-term debt / equity-0.060.160.620.991.011.31
Interest cover15.9022.3011.8621.5520.4226.2359.71
Efficiency & per share
Fixed asset turnover-5.295.447.099.627.485.20
Inventory turnover-4.756.066.306.477.095.36
Debtors turnover-4.706.287.216.336.124.86
EPS (₹)6.435.437.9718.0054.1326.7510.01
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0067.8441.5042.69123.4569.3142.46

To see the full year-wise statements and ratios of Infinium Pharmachem Limited, buy the company report.

Board of directors of Infinium Pharmachem Limited

Infinium Pharmachem has 6 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sanjaykumar Viththalbhai Patel
Also directs: Infinium Healthcare Private Limited, Infinium Green Energy Private Limited
Managing Director21 Nov 200322 Years 11 MonthsCurrent
Pravin Bhadabhai Madhani
Also directs: Infinium Healthcare Private Limited, Infinium Green Energy Private Limited
Director01 Dec 201312 Years 11 MonthsCurrent
Mitesh Lavjibhai Chikhaliya
Also directs: Infinium Healthcare Private Limited
Director27 Nov 201015 Years 11 MonthsCurrent
Tarun Ratilal DobariyaDirector14 Oct 20224 Years 0 MonthsCurrent
Vaishakhi Ambrishbhai Shukla
Also directs: Patel Chem Specialities Limited, Praviksha Foods Private Limited, Rushabhdev Infraprojects Private Limited
Director14 Oct 20224 Years 0 MonthsCurrent
Keyur Jagdishchandra Shah
Also directs: DRC Systems India Limited, Pirimid Technologies Limited, Keyur J Shah Advisors Private Limited and 1 more
Director14 Oct 20224 Years 0 MonthsCurrent
View all directors

Peer comparison

Infinium Pharmachem Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Infinium Pharmachem Limitedthis company₹189.63 Cr (FY 2026)₹12.15 Cr6.4%21.8%93Sojitra, Gujarat, India
Syntho Chirals Private Limited₹162.38 Cr (FY 2024)23.0%Hyderabad, Telangana, India
Vivin Drugs & Pharmaceuticals Private Limited₹161.52 Cr (FY 2023)-25.0%Hyderabad, Telangana, India
Valentis Laboratories Private Limited₹160.96 Cr (FY 2025)135.0%Sangareddy, Telangana, India
Everest Organics Limited₹160.17 Cr (FY 2025)-19.0%Medak, Telangana, India
Gujarat Themis Biosyn Ltd₹153.23 Cr (FY 2025)-12.0%Valsad, Gujarat, India
Allchem Lifescience Limited₹152.78 Cr (FY 2025)11.0%Vadodara, Gujarat, India
Rampex Labs Private Limited₹152.68 Cr (FY 2025)16.0%Bollaram Villege, Telangana, India
SPC Life Sciences Limited₹151.89 Cr (FY 2025)-3.0%Vadodara, Gujarat, India

To see the full peer comparison of Infinium Pharmachem Limited, buy the company report.

Auditor

Infinium Pharmachem Limited is audited by ASHOK RAJPARA & CO for the financial year 2023.

Auditor firmFinancial yearFirm registration number
ASHOK RAJPARA & COFY 2023153195W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 64.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.20% and retail and other public shareholders hold 34.90%.

Promoters: 64.90%DII (Domestic Institutional): 0.20%Retail & Others: 34.90%
Sep 2026
QUARTER
64.90% Promoters
0.20% DII (Domestic Institutional)
34.90% Retail & Others
Promoter holding - history
Now 64.90% · Sep 2026High 65.20% · Dec 2025Low 59.90% · Jun 2026
58%60.3%62.5%64.8%67%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 65.20%Mar 2026: 65.20%Jun 2026: 59.90%Sep 2026: 64.90%65.20%59.90%64.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters64.90%59.90%65.20%65.20%
Public35.10%40.10%34.80%34.80%

Charges & borrowings

Open charges
₹92.6 Cr
Satisfied charges
₹65.68 Cr
Breakdown by lending institutions
State Bank of India₹68.88 Cr
Others₹23.72 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
01 Jul 2026101331778Others₹1 CrOpen
20 May 2025101099730State Bank of India₹3.97 CrOpen
25 Jun 2024100938352Others₹3.72 CrOpen
30 Jan 2024100872533Others₹19 CrOpen
20 Mar 2023100702361State Bank of India₹29.98 CrOpen

To see the full charge records of Infinium Pharmachem Limited, buy the company report.

Total charge records: 16 View all charges

Deals & funding

Infinium Pharmachem Limited has 1 deal on record (1 ipo); the latest was in April 2023.

Total deals
1
IPO
1

Deals on record (1 of 1)

WhenDealAmountParties
Apr 2023IPO₹25.26 CrInvestors: Public Market Investors

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Infinium Pharmachem Limited has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 8 overdue payments to 6 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 6)

SupplierAmount dueDue sinceReported on
Balkrishna Boilers Private Limited
Vrihaan Pharmaceutical LLP
an individual supplier
an individual supplier
Goodluck Plastic Industries

To see the full MSME payment records of Infinium Pharmachem Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Infinium Pharmachem has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Infinium Green Energy Private LimitedU40200GJ2022PTC132667

To see the full group structure of Infinium Pharmachem Limited, buy the company report.

Employees & EPFO

Infinium Pharmachem Limited has a workforce of 93 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.

Employee count
93
Active EPFO establishments
1
Employee growth
10.71%

GST

Infinium Pharmachem has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
24AABCI1843B1Z8GujaratActive01 Jul 2017

To see the full GST registrations and return filing status of Infinium Pharmachem Limited, buy the company report.

Recent activity

Infinium Pharmachem Limited has 11 board changes on record since 2003: 9 appointments and 2 cessations. The latest: Nilesh Dharamshi Bhai Patel was appointed as CFO on 13 Dec 2023.

AGM
Infinium Pharmachem Limited last Annual general meeting of members was held on 17 Sep 2026 as per latest MCA records.
Charges
A charge registered on 21 Jul 2022 via Charge ID 100598338 with Others was fully satisfied on 06 Aug 2026.
Charges
A charge registered on 05 Mar 2020 via Charge ID 100354153 with Others was fully satisfied on 06 Aug 2026.
Charges
A charge registered on 27 May 2019 via Charge ID 100274584 with Others was fully satisfied on 05 Aug 2026.
Charges
A charge with State Bank Of India of Rs. 34.93 Cr registered on 17 Jan 2023 with Charge ID 100681791 was modified on 03 Aug 2026.
Charges
A charge with Others of Rs. 1.00 Cr registered on 01 Jul 2026 with Charge ID 101331778 was modified on 29 Jul 2026.
Charges
A charge with Others amounted to Rs. 1.00 Cr with Charge ID 101331778 was registered on 01 Jul 2026.
Charges
A charge with Others of Rs. 19.00 Cr registered on 30 Jan 2024 with Charge ID 100872533 was modified on 29 May 2026.
Filing
Infinium Pharmachem Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with State Bank Of India of Rs. 29.98 Cr registered on 20 Mar 2023 with Charge ID 100702361 was modified on 16 Feb 2026.
Charges
A charge with Others of Rs. 3.72 Cr registered on 25 Jun 2024 with Charge ID 100938352 was modified on 11 Nov 2025.
Charges
A charge registered on 21 Jan 2025 via Charge ID 101046591 with Others was fully satisfied on 20 Aug 2025.

35 earlier events are in the company report.

News

Frequently asked questions

Infinium Pharmachem is an active public limited company based in Sojitra, Gujarat, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 21 November 2003 (23+ years old) and is registered under CIN L24231GJ2003PLC043218. Listed on NSE: INFINIUM.

Infinium Pharmachem reported revenue of ₹189.63 Cr for FY 2025-26 (up 21.8% YoY) based on consolidated financials.

Infinium Pharmachem has 6 current directors:

The latest financial statements of Infinium Pharmachem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 17 September 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Infinium Pharmachem is 24AABCI1843B1Z8, registered in Gujarat.

The CIN (Corporate Identification Number) of Infinium Pharmachem is L24231GJ2003PLC043218. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Infinium Pharmachem is a listed company as per MCA records. Its shares are listed on NSE (symbol: INFINIUM).

Infinium Pharmachem was incorporated on 21 November 2003, making it 23+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Infinium Pharmachem has 1 deal on record (1 ipo); the latest was in April 2023.

The peers of Infinium Pharmachem by revenue are Syntho Chirals Private Limited, Vivin Drugs & Pharmaceuticals Private Limited, Valentis Laboratories Private Limited, Everest Organics Limited, Gujarat Themis Biosyn Ltd and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Nilesh Dharamshi Bhai Patel was appointed as CFO on 13 Dec 2023. Keyur Jagdishchandra Shah was appointed as Director on 14 Oct 2022. Tarun Ratilal Dobariya was appointed as Director on 14 Oct 2022. Infinium Pharmachem has 11 board changes on record in total.

Yes, Infinium Pharmachem is registered as a medium enterprise under Udyam registration (number: UDYAM-GJ-03-0002712).